Luke joined Asset Management Ventures (AMV) in 2013, and is actively focused on data-driven healthcare investments in the biotechnology and digital health sectors, where he has experience in over 20 investments and exits.
While at Asset Management Ventures, he founded 3T Biosciences, a biotechnology company focused on developing novel immunotherapies. Additionally, Luke originated AMV’s investment in Freenome, where he serves as a board observer.
Prior to Asset Management Ventures, Luke led a project team investigating the genomics landscape for Warburg Pincus that contributed to the formation of Helix, a consumer genomics company that raised over $100M from Warburg Pincus, Illumina, Sutter Hill Ventures, Kleiner Perkins, and the Mayo Clinic. He is also responsible for the formation and instruction of the course, “Valuation of Public Companies in the Life Sciences,” at Stanford.
Luke has been quoted in Reuters around the topic of healthcare, interviewed by Fast Company and BuzzFeed News, contributed as a guest columnist for the Timmerman Report, and serves as a mentor to A-Level Capital, a student-run venture fund.
Luke is a Ph.D. candidate in Cancer Biology at Stanford University and received his Bachelor’s in Molecular and Cellular Biology from Johns Hopkins University.
AMV is a venture capital firm investing in
early-stage digital health, technology and
life sciences companies.
2100 Geng Road, Suite 200
Palo Alto, CA
© 2017 Asset Management Ventures
All Rights Reserved